Filter Results:
(299)
Show Results For
- All HBS Web
(299)
- People (1)
- News (83)
- Research (187)
- Multimedia (4)
- Faculty Publications (124)
Show Results For
- All HBS Web
(299)
- People (1)
- News (83)
- Research (187)
- Multimedia (4)
- Faculty Publications (124)
- November 1999
- Case
E.I. du Pont de Nemours and Company (B)
DuPont must decide whether to launch a new non-GM (genetically modified) soybean that is tolerant to chemical sprays. In the face of rapid introductions of GM products by competitors, DuPont faces the challenge of ensuring the identity preservation of its new product... View Details
Keywords: Business Model; Customer Value and Value Chain; Genetics; Agriculture and Agribusiness Industry
West, Jonathan, and Christian G. Kasper. "E.I. du Pont de Nemours and Company (B)." Harvard Business School Case 600-051, November 1999.
- 06 Sep 2016
- News
Connecting Past and Present
Family health was the impetus for Stanley Diamond (MBA 1958), founder of one of the world’s largest genealogy resources. “My family carries the beta thalassemia genetic trait,” a blood disorder. When my nephew was diagnosed, and we then... View Details
- February 2024
- Article
Are Many Sex/Gender Differences Really Power Differences?
By: Adam D. Galinsky, Aurora Turek, Grusha Agarwal, Eric M. Anicich, Derek D. Rucker, Hannah Riley Bowles, Nira Liberman, Chloe Levin and Joe C Magee
This research addresses the long-standing debate about the determinants of sex/gender differences. Evolutionary theorists trace many sex/gender differences back to natural selection and sex-specific adaptations. Sociocultural and biosocial theorists, in contrast,... View Details
Galinsky, Adam D., Aurora Turek, Grusha Agarwal, Eric M. Anicich, Derek D. Rucker, Hannah Riley Bowles, Nira Liberman, Chloe Levin, and Joe C Magee. "Are Many Sex/Gender Differences Really Power Differences?" PNAS Nexus 3, no. 2 (February 2024).
- 01 Mar 2017
- News
Alumni Take Cold Calls in New York City
focused on 23andMe, whose sale of genetic testing kits directly to consumers was challenged by the Food & Drug Administration. Quelch, who coauthored the case, is also on the faculty of the Harvard T.H. Chan School of Public Health. The... View Details
- 01 Jun 2018
- News
Floor It
The sci-fi future for cancer treatment has become a reality, with breakthrough therapies that can use a cancer patient’s genetic information to create personalized treatments or employ the body’s immune response to treat disease. But for... View Details
Keywords: Julia Hanna; illustration by Mengxin Li
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
question—it’s clear.” Simply put, inefficiencies in the development of precision medicine can best be addressed by a business-analysis approach. With the mapping of the human genome completed 15 years ago, the sci-fi concept of using a cancer patient’s View Details
- 01 Feb 2002
- News
As the Future Catches You
genetics revolution is occurring 50 percent faster than the computer revolution; private companies, from IBM to DuPont to L'Oreal, will have the ability to rewrite the source code of life; and nanotechnology will soon produce "biorobots"... View Details
- 17 Nov 2003
- Research & Ideas
The Business of Babies
fertilization (IVF), surrogacy, and adoption demand payments of $10,000 and up. The largest demand in this market consists of infertile couples. Last year, some two million U.S. couples underwent fertility treatments. Additional demand includes same-sex couples, those... View Details
- 23 Nov 2010
- First Look
First Look: November 23
case:http://cb.hbsp.harvard.edu/cb/product/811014-PDF-ENG Generation Health: A Pioneer in Genetics Benefit Management (A) Robert F. Higgins, Jeffrey D. Marrazzo, and Rachel GordonHarvard Business School Case 810-007 Generation Health, a... View Details
Keywords: Sean Silverthorne
- Web
The Ownership Project | Institute for Business in Global Society
social progress. Learn how evolving concepts of ownership - from real estate to AI, genetic data to media - are reshaping capitalism and creating new challenges and opportunities for business leaders. Previous Play Video duration: 1:07... View Details
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details
Keywords: Genetics; Information Technology; Business Model; Disruptive Innovation; Biotechnology Industry; Information Technology Industry; Semiconductor Industry; Medical Devices and Supplies Industry
Yoffie, David B., Dharmesh M Mehta, and Rachel Sha. "Note on the Convergence Between Genomics & Information Technology." Harvard Business School Background Note 705-500, June 2005. (Revised July 2006.)
- 15 Apr 2014
- First Look
First Look: April 15
Pooled Income Funds. Purchase this case: http://hbr.org/product/choosing-a-charitable-giving-vehicle/an/314073-PDF-ENG Harvard Business School Case 514-086 23andMe: Genetic Testing for Consumers (A) On November 22, 2013, the... View Details
Keywords: Sean Silverthorne
- Profile
Jeremy King
As an undergraduate, Jeremy King pursued a degree in biology, studying ecology, genetics and animal behavior. Though he considered medicine a career, he found himself working with a very different animal. "I interned in the more... View Details
- 26 Sep 2024
- Blog Post
Syngenta Tomato Vision
years. However, only about 2% of all tested varieties in the greenhouse end up commercialized! Syngenta’s technology differs from genetically modified organisms (GMO) as they only leverage genes that exist naturally in tomatoes, whereas... View Details
- June 2011 (Revised October 2013)
- Case
Gene Patents (A)
By: Richard Hamermesh, David Kiron and Phillip Andrews
In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues... View Details
Keywords: Courts and Trials; Patents; Genetics; Judgments; Science-Based Business; Biotechnology Industry; United States
Hamermesh, Richard, David Kiron, and Phillip Andrews. "Gene Patents (A)." Harvard Business School Case 811-089, June 2011. (Revised October 2013.)
- 02 Jul 2001
- Research & Ideas
Ray A. Goldberg
issues," he beams, "from land reform in Mexico to the development of the genetically modified tomato." "The genetic research revolution is changing our global economy and society more... View Details
- Profile
Paris Wallace
Eric Boutin in 2008 in his last year at HBS. Good Start Genetics is now a successful late stage venture with more than 150 employees. The company offers a fertility diagnostic that allows parents to determine if their children are at risk... View Details
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
genetically modified foods in Europe. Betting the company on a "life sciences" vision, Shapiro had sold or spun off Monsanto's traditional chemical businesses and moved aggressively to acquire seed companies. Dazzled by the... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- June 1997 (Revised September 1997)
- Case
Genset Initial Public Offering (B)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Supplements the (A) case. View Details
Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (B)." Harvard Business School Case 297-097, June 1997. (Revised September 1997.)